-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Kc5DMnoABxjptdQm9O7FrDAT/3bOKOKgAint2W28sC51LiTOnrpiPxZ6ukRhSraI EowJObcq9clDG44r9Rgx4Q== 0000950144-95-002994.txt : 19951107 0000950144-95-002994.hdr.sgml : 19951107 ACCESSION NUMBER: 0000950144-95-002994 CONFORMED SUBMISSION TYPE: 10-C PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19951102 FILED AS OF DATE: 19951106 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESPONSE TECHNOLOGIES INC CENTRAL INDEX KEY: 0000763098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 621212264 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-C SEC ACT: 1934 Act SEC FILE NUMBER: 001-09922 FILM NUMBER: 95587493 BUSINESS ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 BUSINESS PHONE: 9017617000 MAIL ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 FORMER COMPANY: FORMER CONFORMED NAME: BIOTHERAPEUTICS INC DATE OF NAME CHANGE: 19891221 10-C 1 RESPONSE TECHNOLOGIES, INC. 10-C 11-2-95 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-C Report by Issuer of Securities Quoted on NASDAQ Interdealer Quotation System Filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and Rule 13a-17 or 15d-17 thereunder Response Oncology, Inc. - -------------------------------------------------------------------------------- (Exact name of Issuer as specified in charter) 1775 Moriah Woods Blvd., Memphis, TN 38117 - -------------------------------------------------------------------------------- (Address of principal executive offices) Issuer's telephone number, including area code 901-761-7000 -------------------------------- I. CHANGE IN NUMBER OF SHARES OUTSTANDING 1. Title of security Common Stock ---------------------------------------------------------- 2. Number of shares outstanding before the change 34,932,615 ----------------------------- 3. Number of shares outstanding after the change 6,986,523 (Approximate) ------------------------------ 4. Effective date of change November 2, 1995 --------------------------------------------------- 5. Method of change: Specify method (such as merger, acquisition, exchange, distribution, stock split, reverse split, acquisition of stock for treasury, etc.) reverse split ---------------------------------------------------------------------- Give brief description of transaction decrease number of authorized ----------------------------------- shares from 60,000,000 shares, $.002 par value, to 30,000,000 shares, $.01 par - ------------------------------------------------------------------------------- value, with a corresponding reclassification to which each issued and - ------------------------------------------------------------------------------- outstanding share will be reclassified, converted, and charged into - ------------------------------------------------------------------------------- one-fifth (1/5) of an issued and outstanding share. Fractional shares to be - ------------------------------------------------------------------------------- redeemed for cash. - ------------------------------------------------------------------------------- II. CHANGE IN NAME OF ISSUER 1. Name prior to change Response Technologies, Inc. ------------------------------------------------------- 2. Name after change Response Oncology, Inc. ---------------------------------------------------------- 3. Effective date of charter amendment changing name November 2, 1995 --------------------------- 4. Date of shareholder approval of change, if required November 1, 1995 ------------------------ Date 11/6/95 ------- /s/ Daryl P. Johnson, Chief Financial Officer --------------------------------------------- (Officer's signature & title) -----END PRIVACY-ENHANCED MESSAGE-----